Boryung Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 03:34 am EST
Share
Boryung Corporation reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 43.16 million compared to KRW 85.91 million a year ago. Net income was KRW 11,936.36 million compared to KRW 21,952.75 million a year ago. Basic earnings per share from continuing operations was KRW 181 compared to KRW 333 a year ago. Diluted earnings per share from continuing operations was KRW 181 compared to KRW 333 a year ago. Basic earnings per share was KRW 181 compared to KRW 333 a year ago.
For the nine months, sales was KRW 163.25 million compared to KRW 314.52 million a year ago. Net income was KRW 34,606.61 million compared to KRW 48,233.74 million a year ago. Basic earnings per share from continuing operations was KRW 525 compared to KRW 732 a year ago. Diluted earnings per share from continuing operations was KRW 525 compared to KRW 730 a year ago. Basic earnings per share was KRW 525 compared to KRW 732 a year ago.
Boryung Corp, formerly Boryung Pharm Co Ltd, is a Korea-based company principally engaged in the manufacture and sale of pharmaceutical products. The Company mainly manufactures and distributes pharmaceutical products including antihypertensive drugs, gastrointestinal disorder drugs, antibiotics, gastric ulcer drugs, oral antibiotics, anticancer drugs and antihyperlipidemic drugs, among others. The Company distributes its products in domestic and overseas markets.